ES2228118T3 - Procedimiento para controlar la accion de un farmaco inhibidor de proteasoma. - Google Patents

Procedimiento para controlar la accion de un farmaco inhibidor de proteasoma.

Info

Publication number: ES2228118T3
Authority: ES; Spain
Prior art keywords: proteasome; activity; sample; mammal; blood
Prior art date: 1998-10-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES99952027T

Other languages

English (en)

Spanish (es)

Inventor

Gopalakrishna R. Vaddi

Ross L. Stein

Lawrence R. Dick

Vito J. Palombella

Eric S. Lightcap

Peter J. Elliott

Julian Adams

Teresa A. Mccormack

Stephen J. Brand

Dan R. Burns

Vincent Chau

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Millennium Pharmaceuticals Inc

Original Assignee

Millennium Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-20

Filing date

1999-10-19

Publication date

2005-04-01

1999-10-19 Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc

2005-04-01 Application granted granted Critical

2005-04-01 Publication of ES2228118T3 publication Critical patent/ES2228118T3/es

2019-10-19 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108090000708 Proteasome Endopeptidase Complex Proteins 0.000 title claims abstract description 239
102000004245 Proteasome Endopeptidase Complex Human genes 0.000 title claims abstract description 236
238000000034 method Methods 0.000 title claims abstract description 94
230000009471 action Effects 0.000 title claims abstract description 15
230000002401 inhibitory effect Effects 0.000 title description 3
230000000694 effects Effects 0.000 claims abstract description 208
239000012472 biological sample Substances 0.000 claims abstract description 75
241000124008 Mammalia Species 0.000 claims abstract description 72
229940079156 Proteasome inhibitor Drugs 0.000 claims abstract description 72
239000003207 proteasome inhibitor Substances 0.000 claims abstract description 72
239000003814 drug Substances 0.000 claims abstract description 48
229940079593 drug Drugs 0.000 claims abstract description 46
230000003285 pharmacodynamic effect Effects 0.000 claims abstract description 8
239000000523 sample Substances 0.000 claims description 71
239000008280 blood Substances 0.000 claims description 62
210000004369 blood Anatomy 0.000 claims description 61
238000012360 testing method Methods 0.000 claims description 48
210000004027 cell Anatomy 0.000 claims description 32
239000003112 inhibitor Substances 0.000 claims description 32
241000700159 Rattus Species 0.000 claims description 30
108090000623 proteins and genes Proteins 0.000 claims description 28
102000004169 proteins and genes Human genes 0.000 claims description 27
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
201000010099 disease Diseases 0.000 claims description 25
238000005259 measurement Methods 0.000 claims description 19
ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 17
210000000601 blood cell Anatomy 0.000 claims description 16
239000006166 lysate Substances 0.000 claims description 16
210000001519 tissue Anatomy 0.000 claims description 16
241000699670 Mus sp. Species 0.000 claims description 15
241000288906 Primates Species 0.000 claims description 11
230000001575 pathological effect Effects 0.000 claims description 11
206010028980 Neoplasm Diseases 0.000 claims description 10
102000035195 Peptidases Human genes 0.000 claims description 10
108091005804 Peptidases Proteins 0.000 claims description 10
KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 10
239000013074 reference sample Substances 0.000 claims description 10
235000019833 protease Nutrition 0.000 claims description 9
239000013592 cell lysate Substances 0.000 claims description 8
-1 peptidyl aldehydes Chemical class 0.000 claims description 8
125000003180 beta-lactone group Chemical group 0.000 claims description 7
230000017854 proteolysis Effects 0.000 claims description 7
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 6
210000000056 organ Anatomy 0.000 claims description 6
238000001574 biopsy Methods 0.000 claims description 5
210000002700 urine Anatomy 0.000 claims description 5
241000282412 Homo Species 0.000 claims description 4
239000012190 activator Substances 0.000 claims description 4
210000001072 colon Anatomy 0.000 claims description 4
125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims description 2
AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 claims description 2
125000005620 boronic acid group Chemical group 0.000 claims description 2
AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical class C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 claims description 2
239000012530 fluid Substances 0.000 claims description 2
239000002243 precursor Substances 0.000 claims description 2
210000001179 synovial fluid Anatomy 0.000 claims description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N epoxyketone group Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 1
210000000663 muscle cell Anatomy 0.000 claims 1
125000001151 peptidyl group Chemical group 0.000 claims 1
238000007390 skin biopsy Methods 0.000 claims 1
238000001727 in vivo Methods 0.000 abstract description 10
238000012544 monitoring process Methods 0.000 abstract 2
239000000758 substrate Substances 0.000 description 48
230000005764 inhibitory process Effects 0.000 description 39
238000001990 intravenous administration Methods 0.000 description 38
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
239000000872 buffer Substances 0.000 description 22
GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 20
241001465754 Metazoa Species 0.000 description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 18
210000000265 leukocyte Anatomy 0.000 description 16
230000007423 decrease Effects 0.000 description 14
108090000765 processed proteins & peptides Proteins 0.000 description 14
238000003556 assay Methods 0.000 description 13
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
241000283973 Oryctolagus cuniculus Species 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
238000011282 treatment Methods 0.000 description 12
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 11
230000004913 activation Effects 0.000 description 11
239000000243 solution Substances 0.000 description 11
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 9
108010022579 ATP dependent 26S protease Proteins 0.000 description 9
239000007995 HEPES buffer Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
210000001995 reticulocyte Anatomy 0.000 description 8
102000001554 Hemoglobins Human genes 0.000 description 7
108010054147 Hemoglobins Proteins 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
230000001276 controlling effect Effects 0.000 description 7
230000006870 function Effects 0.000 description 7
239000008188 pellet Substances 0.000 description 7
210000005259 peripheral blood Anatomy 0.000 description 7
239000011886 peripheral blood Substances 0.000 description 7
235000010323 ascorbic acid Nutrition 0.000 description 6
229960005070 ascorbic acid Drugs 0.000 description 6
239000011668 ascorbic acid Substances 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
210000003743 erythrocyte Anatomy 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
210000004976 peripheral blood cell Anatomy 0.000 description 6
230000008569 process Effects 0.000 description 6
241000282693 Cercopithecidae Species 0.000 description 5
108090000317 Chymotrypsin Proteins 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
239000002253 acid Substances 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
229960002376 chymotrypsin Drugs 0.000 description 5
238000006731 degradation reaction Methods 0.000 description 5
229940088598 enzyme Drugs 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
108090000631 Trypsin Proteins 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
239000006096 absorbing agent Substances 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
238000002512 chemotherapy Methods 0.000 description 4
230000001419 dependent effect Effects 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
230000003993 interaction Effects 0.000 description 4
238000010253 intravenous injection Methods 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
230000002797 proteolythic effect Effects 0.000 description 4
230000035939 shock Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
UVFAEQZFLBGVRM-MSMWPWNWSA-N succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CCC(O)=O)CC(C)C)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C1=CC=C(O)C=C1 UVFAEQZFLBGVRM-MSMWPWNWSA-N 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
239000012588 trypsin Substances 0.000 description 4
230000003442 weekly effect Effects 0.000 description 4
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000002757 inflammatory effect Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000003607 modifier Substances 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
239000000047 product Substances 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
238000012453 sprague-dawley rat model Methods 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
210000001550 testis Anatomy 0.000 description 3
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
238000009010 Bradford assay Methods 0.000 description 2
206010006895 Cachexia Diseases 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
102000005483 Cell Cycle Proteins Human genes 0.000 description 2
108010031896 Cell Cycle Proteins Proteins 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
241001529936 Murinae Species 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
206010028289 Muscle atrophy Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
241000282887 Suidae Species 0.000 description 2
102000040945 Transcription factor Human genes 0.000 description 2
108091023040 Transcription factor Proteins 0.000 description 2
108090000848 Ubiquitin Proteins 0.000 description 2
102000044159 Ubiquitin Human genes 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000009795 derivation Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
238000010228 ex vivo assay Methods 0.000 description 2
238000005558 fluorometry Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000028709 inflammatory response Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
201000000585 muscular atrophy Diseases 0.000 description 2
PDUGCIODBWSTTA-NVQXNPDNSA-N n-[(2s)-1-[[2-[[(2s)-5-(diaminomethylideneamino)-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]benzamide Chemical compound N([C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C(=O)C1=CC=CC=C1 PDUGCIODBWSTTA-NVQXNPDNSA-N 0.000 description 2
238000010606 normalization Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000035515 penetration Effects 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
238000011002 quantification Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000006965 reversible inhibition Effects 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000004448 titration Methods 0.000 description 2
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
JBIJLHTVPXGSAM-UHFFFAOYSA-N 2-naphthylamine Chemical compound C1=CC=CC2=CC(N)=CC=C21 JBIJLHTVPXGSAM-UHFFFAOYSA-N 0.000 description 1
UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
108050006400 Cyclin Proteins 0.000 description 1
102000016736 Cyclin Human genes 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
206010021137 Hypovolaemia Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
102000008192 Lactoglobulins Human genes 0.000 description 1
108010060630 Lactoglobulins Proteins 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
208000028389 Nerve injury Diseases 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241000282579 Pan Species 0.000 description 1
241000282520 Papio Species 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000004365 Protease Substances 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
108010005705 Ubiquitinated Proteins Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000002141 anti-parasite Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
150000001642 boronic acid derivatives Chemical class 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
150000005693 branched-chain amino acids Chemical class 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
230000009920 chelation Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000003436 cytoskeletal effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000008406 drug-drug interaction Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012997 ficoll-paque Substances 0.000 description 1
238000007421 fluorometric assay Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
230000036541 health Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
LPTIRUACFKQDHZ-UHFFFAOYSA-N hexadecyl sulfate;hydron Chemical class CCCCCCCCCCCCCCCCOS(O)(=O)=O LPTIRUACFKQDHZ-UHFFFAOYSA-N 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
229940043355 kinase inhibitor Drugs 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
241001515942 marmosets Species 0.000 description 1
239000000463 material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000008764 nerve damage Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
239000003757 phosphotransferase inhibitor Substances 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
244000000040 protozoan parasite Species 0.000 description 1
238000000746 purification Methods 0.000 description 1
239000008213 purified water Substances 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008521 reorganization Effects 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
238000001223 reverse osmosis Methods 0.000 description 1
241000894007 species Species 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000010902 straw Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000010998 test method Methods 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
239000000225 tumor suppressor protein Substances 0.000 description 1
238000010798 ubiquitination Methods 0.000 description 1
230000034512 ubiquitination Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
230000008673 vomiting Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

ES99952027T 1998-10-20 1999-10-19 Procedimiento para controlar la accion de un farmaco inhibidor de proteasoma. Expired - Lifetime ES2228118T3 (es)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US10491898P	1998-10-20	1998-10-20
US104918P		1998-10-20
US13138199P	1999-04-28	1999-04-28
US131381P		1999-04-28

Publications (1)

Publication Number	Publication Date
ES2228118T3 true ES2228118T3 (es)	2005-04-01

Family

ID=26802081

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES99952027T Expired - Lifetime ES2228118T3 (es)	1998-10-20	1999-10-19	Procedimiento para controlar la accion de un farmaco inhibidor de proteasoma.

Country Status (15)

Country	Link
US (1)	US6613541B1 (fr)
EP (1)	EP1123412B1 (fr)
JP (1)	JP4503182B2 (fr)
KR (1)	KR20010080267A (fr)
CN (1)	CN1331752A (fr)
AT (1)	ATE278803T1 (fr)
AU (1)	AU762373B2 (fr)
BR (1)	BR9914648A (fr)
CA (1)	CA2347275C (fr)
DE (1)	DE69920940T2 (fr)
ES (1)	ES2228118T3 (fr)
HK (1)	HK1040533A1 (fr)
IL (2)	IL142647A0 (fr)
NZ (1)	NZ511197A (fr)
WO (1)	WO2000023614A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1326632B1 (fr)	2000-10-12	2006-09-06	Viromics Gmbh	Inhibiteurs du proteasome pour le traitement d'infections d'hepatite virale
DE10051716A1 (de) *	2000-10-12	2002-04-25	Ulrich Schubert	Mittel zur Hemmung der Freisetzung, Reifung und Replikation von Retroviren
EP1341414B1 (fr)	2000-11-16	2013-01-02	The Regents of The University of California	Taxon d'actinomycete marin utilise pour la decouverte de medicaments et de produits de fermentation
EP2388254B1 (fr) *	2002-02-01	2016-08-10	Promega Corporation	Analyse de protéase bioluminescente
ATE481104T1 (de)	2002-04-05	2010-10-15	Virologik Gmbh	Mittel zur behandlung von flaviviridae- infektionen
US7176232B2 (en)	2002-06-24	2007-02-13	The Regents Of The University Of California	Salinosporamides and methods for use thereof
DE10232902A1 (de) *	2002-07-19	2004-01-29	Bayer Cropscience Ag	Verfahren zum Identifizieren von Inhibitoren des 20S und 26S Proteasoms
US20050049294A1 (en) *	2003-06-20	2005-03-03	Michael Palladino	Methods of using [3.2.0] heterocyclic compounds and analogs thereof
CN101791306A (zh)	2003-06-20	2010-08-04	加利福尼亚大学董事会	盐孢菌酰胺及其使用方法
CA2530479C (fr) *	2003-08-08	2010-01-19	F. Hoffmann-La Roche Ag	Utilisation de la sous-unite 3 de proteine activatrice de proteasome (pse3) comme marqueur de cancer colorectal
US7576206B2 (en)	2003-08-14	2009-08-18	Cephalon, Inc.	Proteasome inhibitors and methods of using the same
US7223745B2 (en)	2003-08-14	2007-05-29	Cephalon, Inc.	Proteasome inhibitors and methods of using the same
US7416854B2 (en) *	2004-01-22	2008-08-26	Promega Corporation	Luminogenic and nonluminogenic multiplex assay
US7553632B2 (en) *	2004-01-22	2009-06-30	Promega Corporation	Luminogenic and nonluminogenic multiplex assay
CN102174076A (zh)	2004-04-15	2011-09-07	普罗特奥里克斯公司	用于抑制蛋白酶体酶的化合物
US8198270B2 (en) *	2004-04-15	2012-06-12	Onyx Therapeutics, Inc.	Compounds for proteasome enzyme inhibition
JP2007535559A (ja)	2004-04-30	2007-12-06	ネレアスファーマシューティカルズインコーポレイテッド	［３．２．０］複素環式化合物及びその使用法
US7579371B2 (en)	2004-04-30	2009-08-25	Nereus Pharmaceuticals, Inc.	Methods of using [3.2.0] heterocyclic compounds and analogs thereof
SG185963A1 (en) *	2004-05-10	2012-12-28	Onyx Therapeutics Inc	Compounds for enzyme inhibition
CA2584515A1 (fr) *	2004-10-20	2006-04-27	Proteolix, Inc.	Composes pour inhibition d'enzymes
WO2006060676A1 (fr)	2004-12-03	2006-06-08	Dana Farber Cancer Institute	Compositions et procedes destines au traitement des maladies neoplastiques
US7468383B2 (en)	2005-02-11	2008-12-23	Cephalon, Inc.	Proteasome inhibitors and methods of using the same
US20060193844A1 (en) *	2005-02-28	2006-08-31	Proteolix, Inc.	Methods for enzyme inhibition
US20070048812A1 (en) *	2005-09-01	2007-03-01	Moravec Richard A	Cell-based luminogenic and nonluminogenic proteasome assays
LT2623113T (lt)	2005-11-09	2017-07-10	Onyx Therapeutics, Inc.	Junginiai, skirti fermentų slopinimui
AR057227A1 (es) *	2005-12-09	2007-11-21	Centocor Inc	Metodo para usar antagonistas de il6 con inhibidores del proteasoma
PL2041158T3 (pl)	2006-06-19	2013-08-30	Onyx Therapeutics Inc	Peptydowe epoksyketony do hamowania proteasomu
US20080118940A1 (en) *	2006-11-22	2008-05-22	Maher Albitar	Proteasomal peptidase activity and the use thereof in clinical applications
US7824698B2 (en)	2007-02-02	2010-11-02	Nereus Pharmaceuticals, Inc.	Lyophilized formulations of Salinosporamide A
AU2008239654A1 (en)	2007-04-13	2008-10-23	Promega Corporation	Luminescent live and dead cell assay
ES2684340T3 (es)	2007-10-04	2018-10-02	Onyx Therapeutics, Inc.	Inhibidores de proteasa epoxi cetona de péptidos cristalinos y síntesis de cetoepóxidos de aminoácidos
US8394816B2 (en)	2007-12-07	2013-03-12	Irene Ghobrial	Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
BRPI0912234A2 (pt)	2008-05-12	2015-10-06	Nereus Pharmaceuticals Inc	derivados de salinosporamida como inibidores de proteassomas
EP2349313A4 (fr)	2008-10-21	2012-08-29	Onyx Therapeutics Inc	Thérapie de combinaison avec des peptides époxycétones
TWI504598B (zh)	2009-03-20	2015-10-21	Onyx Therapeutics Inc	結晶性三肽環氧酮蛋白酶抑制劑
US20110053197A1 (en) *	2009-08-25	2011-03-03	Quest Diagnostics Investments Incorporated	Ubiquitin proteasome system profiling and the use thereof in clinical applications for cancer diagnosis
US20110053199A1 (en) *	2009-08-25	2011-03-03	Quest Diagnostics Investments Incorporated	Ubiquitin proteasome system profiling and the use thereof in clinical applications for cancer diagnosis
US20110053198A1 (en) *	2009-08-25	2011-03-03	Quest Diagnostics Investments Incorporated	Ubiquitin proteasome system profiling and the use thereof in clinical applications for proliferative hematological disorders
WO2011060179A1 (fr)	2009-11-13	2011-05-19	Onyx Therapeutics, Inc	Utilisation de peptides epoxycetones pour la suppression de la metastase
WO2011087822A1 (fr)	2009-12-22	2011-07-21	Cephalon, Inc.	Inhibiteurs du protéasome et leurs procédés de préparation, d'épuration et d'utilisation
EA201290844A1 (ru)	2010-03-01	2013-03-29	Оникс Терапьютикс, Инк.	Соединения для ингибирования иммунопротеасом
BR112012025264A2 (pt)	2010-04-07	2019-09-24	Onyx Therapeutics Inc	inibidor de imunoproteassoma de e´poxicetona peptídica cristalina.
US20140105921A1 (en)	2012-07-09	2014-04-17	Onyx Therapeutics, Inc.	Prodrugs of Peptide Epoxy Ketone Protease Inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5340736A (en) *	1991-05-13	1994-08-23	The President & Fellows Of Harvard College	ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
WO1994017816A1 (fr)	1993-02-10	1994-08-18	The President And Fellows Of Harvard College	Role de la proteolyse dependant de l'ubiquitine atp dans la presentation de l'antigene restreint chm-1 et inhibiteurs utilises a cet effet
US5693617A (en) *	1994-03-15	1997-12-02	Proscript, Inc.	Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en)	1994-03-18	2003-12-09	The President And Fellows Of Harvard College	Proteasome regulation of NF-KB activity
US5574017A (en)	1994-07-05	1996-11-12	Gutheil; William G.	Antibacterial agents
US6083903A (en) *	1994-10-28	2000-07-04	Leukosite, Inc.	Boronic ester and acid compounds, synthesis and uses
US5614649A (en)	1994-11-14	1997-03-25	Cephalon, Inc.	Multicatalytic protease inhibitors
US5804560A (en) *	1995-01-06	1998-09-08	Sibia Neurosciences, Inc.	Peptide and peptide analog protease inhibitors
US6335358B1 (en) *	1995-04-12	2002-01-01	President And Fellows Of Harvard College	Lactacystin analogs
CA2219867A1 (fr)	1997-10-31	1999-04-30	Jiangping Wu	Utilisation d'inhibiteurs du proteasome dans le traitement du cancer, de l'inflammation, des maladies auto-immunes, du rejet de greffe et du choc septique
US6617171B2 (en) *	1998-02-27	2003-09-09	The General Hospital Corporation	Methods for diagnosing and treating autoimmune disease
EP1088100A2 (fr) *	1998-06-13	2001-04-04	Zarpex Biosciences Limited	Activite de proteasomes

1999
- 1999-10-19 WO PCT/US1999/024356 patent/WO2000023614A1/fr not_active Ceased
- 1999-10-19 EP EP99952027A patent/EP1123412B1/fr not_active Expired - Lifetime
- 1999-10-19 BR BR9914648-7A patent/BR9914648A/pt not_active IP Right Cessation
- 1999-10-19 DE DE69920940T patent/DE69920940T2/de not_active Expired - Lifetime
- 1999-10-19 AU AU64333/99A patent/AU762373B2/en not_active Expired
- 1999-10-19 US US09/419,551 patent/US6613541B1/en not_active Expired - Lifetime
- 1999-10-19 IL IL14264799A patent/IL142647A0/xx active IP Right Grant
- 1999-10-19 HK HK02101045.1A patent/HK1040533A1/zh unknown
- 1999-10-19 CN CN99813797A patent/CN1331752A/zh active Pending
- 1999-10-19 CA CA002347275A patent/CA2347275C/fr not_active Expired - Lifetime
- 1999-10-19 AT AT99952027T patent/ATE278803T1/de not_active IP Right Cessation
- 1999-10-19 JP JP2000577321A patent/JP4503182B2/ja not_active Expired - Lifetime
- 1999-10-19 NZ NZ511197A patent/NZ511197A/en unknown
- 1999-10-19 KR KR1020017004966A patent/KR20010080267A/ko not_active Withdrawn
- 1999-10-19 ES ES99952027T patent/ES2228118T3/es not_active Expired - Lifetime
2001
- 2001-04-17 IL IL142647A patent/IL142647A/en not_active IP Right Cessation

Also Published As

Publication number	Publication date
WO2000023614A1 (fr)	2000-04-27
WO2000023614A8 (fr)	2000-07-13
DE69920940D1 (de)	2004-11-11
IL142647A (en)	2006-04-10
CN1331752A (zh)	2002-01-16
BR9914648A (pt)	2001-11-27
CA2347275A1 (fr)	2000-04-27
AU6433399A (en)	2000-05-08
JP2002527114A (ja)	2002-08-27
EP1123412B1 (fr)	2004-10-06
KR20010080267A (ko)	2001-08-22
AU762373B2 (en)	2003-06-26
HK1040533A1 (zh)	2002-06-14
US6613541B1 (en)	2003-09-02
IL142647A0 (en)	2002-03-10
EP1123412A1 (fr)	2001-08-16
ATE278803T1 (de)	2004-10-15
JP4503182B2 (ja)	2010-07-14
CA2347275C (fr)	2010-03-09
DE69920940T2 (de)	2005-11-17
NZ511197A (en)	2003-08-29

Publication	Publication Date	Title
ES2228118T3 (es)	2005-04-01	Procedimiento para controlar la accion de un farmaco inhibidor de proteasoma.
Lu et al.	2020	High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity
Schmidtke et al.	2000	Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20 S proteasome
Waxman et al.	1985	Protease La, the lon gene product, cleaves specific fluorogenic peptides in an ATP-dependent reaction.
Lancellotti et al.	2010	Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress
Miekus et al.	2019	MMP-14 degrades tropoelastin and elastin
Raymond et al.	2009	α2-Macroglobulin capture allows detection of mast cell chymase in serum and creates a reservoir of angiotensin II-generating activity
Chitsamankhun et al.	2024	Cathepsin C in health and disease: from structural insights to therapeutic prospects
Barrett	1980	Cathepsin D: the lysosomal aspartic proteinase
Chagas et al.	1997	A comparison of the enzymatic properties of the major cysteine proteinases from Trypanosoma congolense and Trypanosoma cruzi
ES2267541T3 (es)	2007-03-16	Medicion enzimatica del acido micofenolico.
Uemura et al.	2017	Activation of MMP-9 activity by acrolein in saliva from patients with primary Sjögren’s syndrome and its mechanism
Berthon et al.	2007	Regulation of ubiquitin–proteasome system, caspase enzyme activities, and extracellular proteinases in rat soleus muscle in response to unloading
Nieman et al.	2004	The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1
ES2297742T3 (es)	2008-05-01	Sustratos peptidicos reconocidos por la toxina botulinica de tipo a, bont/a y sus usos.
Poras et al.	2013	A sensitive fluorigenic substrate for selective in vitro and in vivo assay of leukotriene A4 hydrolase activity
Yasuda et al.	2005	A new selective substrate for cathepsin E based on the cleavage site sequence of α2-macroglobulin
EP2748616B1 (fr)	2018-08-08	Inhibiteurs thermostables d'activation du système de coagulation du sang au contact de surfaces étrangères
Dębowski et al.	2016	Interactions between trypsin and its peptidic inhibitors studied by isothermal titration calorimetry (ITC)
ES2276951T3 (es)	2007-07-01	Nuevos sustratos cromogenos y su utilizacion para la dosificacion de la actividad de carboxipeptidasas.
Liu et al.	2018	Effects of acetazolamide on the conformations and activities of digestive enzymes: pepsin and trypsin
Korkmaz et al.	2011	Discriminating between the activities of human cathepsin G and chymase using fluorogenic substrates
Jyrkäs et al.	2025	In Vitro and In Vivo Catabolite Profiles of Leuprorelin in Rat and the Effects of NADPH in Leuprorelin Catabolism
US20240358731A1 (en)	2024-10-31	Sumo pathway as an oxygen sensor relevant to the pathophysiology of pulmonary artery hypertension and cardiac arrhythmia
Tsihlis et al.	2013	Nitric oxide may inhibit neointimal hyperplasia by decreasing isopeptidase T levels and activity in the vasculature